We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Candidate Cancer Drug Blocks Proteins That Inhibit Apoptosis

By LabMedica International staff writers
Posted on 13 Apr 2011
Print article
An orally deliverable drug that blocks the activity of proteins that prevent cells from entering apoptosis has been found to shrink tumors significantly in animals with only minimal side effects.

The drug, AT-406, mimics the action of the protein Smac (second mitochondria-derived activator of caspases), a mitochondrial protein that enables apoptosis, possibly by neutralizing one or more members of the IAP family of apoptosis inhibitory proteins. The inhibitors of apoptosis (IAP) are a family of functionally- and structurally-related proteins, which serve as endogenous inhibitors of programmed cell death. The human IAP family consists of at least six members, and IAP homologs have been identified in numerous organisms.

Smac has been shown to exit mitochondria and enter the cytosol during apoptosis triggered by UV- or gamma-irradiation. In the cytosol Smac moderates the caspase inhibition of IAPs.

Investigators at the University of Michigan (Ann Arbor, USA) first synthesized AT-406 in 2006. Since then they have demonstrated that the drug blocked IAP activity in a variety of cell free systems. In the current study, which was published in the March 28, 2011, issue of the Journal of Medicinal Chemistry, they examined the effect of AT-406 on human cancer cells growing in culture and on tumors in animal models.

They found that the drug inhibited cancer cell growth in various human cancer cell lines. It had good oral bioavailability in mice, rats, nonhuman primates, and dogs, was highly effective in induction of apoptosis in xenograft tumors, and was capable of complete inhibition of tumor growth.

"Removing key apoptosis blockades in tumor cells is a completely new cancer therapeutic approach and could have benefit for the treatment of many types of human tumors,” said senior author Dr. Shaomeng Wang, professor of medicine at the University of Michigan.

Patent applications covering the drug are exclusively licensed to Ascenta Therapeutics (Malvern, PA, USA), a privately held, clinical stage biopharmaceutical company cofounded by Dr. Wang. After extensive testing, in 2010 Ascenta began the first clinical trial of AT-406 as a potential cancer treatment.

Related Links:

University of Michigan
Ascenta Therapeutics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.